328 related articles for article (PubMed ID: 19476985)
1. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
[TBL] [Abstract][Full Text] [Related]
7. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
8. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA;
J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238
[TBL] [Abstract][Full Text] [Related]
10. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
[TBL] [Abstract][Full Text] [Related]
12. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
14. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
15. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
Alexander BM; Chen MH; Carroll P; D'Amico AV
Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
[TBL] [Abstract][Full Text] [Related]
17. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
Bates AT; Pickles T; Paltiel C
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):148-53. PubMed ID: 15850915
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.
Beard C; Chen MH; Cote K; Loffredo M; Renshaw A; Hurwitz M; D'Amico AV
Urology; 2005 Nov; 66(5):1020-3. PubMed ID: 16286116
[TBL] [Abstract][Full Text] [Related]
19. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
